The more advanced developments that led to the commercialization of the first products, have identified as a target the molecule CD19, expressed in all leukemia acute lymphoblastic leukemia (ALL) (3) and in Non-Hodgkin Lymphoma (NHL) (4), such as diffuse (D) large B-cell lymphoma (LBCL) (5), follicular lymphoma (FL) (6), mantle-cel lymphoma (MCL) (7) and the molecule B-cell maturation antigen (BCMA), expresses in multiple myeloma (MM) (8, 9). Here, TNFRSF17 is linked to acute lymphoblastic leukemia.